Indibulin

Drug Profile

Indibulin

Alternative Names: D-24851; ZIO-301; Zybulin

Latest Information Update: 30 Sep 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Baxter Healthcare Corporation
  • Developer ZIOPHARM Oncology
  • Class Acetamides; Antineoplastics; Indoles; Small molecules
  • Mechanism of Action Mitosis inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Breast cancer; Solid tumours

Most Recent Events

  • 30 Sep 2015 Discontinued - Phase-I for Solid tumours (Combination therapy) in USA (PO)
  • 30 Sep 2015 Discontinued - Phase-I for Solid tumours (Monotherapy) in Netherlands (PO)
  • 30 Sep 2015 Discontinued - Phase-I/II for Breast cancer (Late-stage disease, Monotherapy) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top